Search

Author/Creator Tuttle, J

1. A-04 Acute Sports-Related Concussion Associations Between Cognitive Symptoms, Memory Performance, and Default Mode Network Hub Connectivity. (13th July 2022)

Authors:
Bouchard, H C; Schultz, D H; Higgins, K; Laing, J M; Rodriguez, A I; Carlson, E; Tuttle, J; Mayer, M; Albers, L; Maerlender, A; Neta, M; Savage, C R
Journal:
Archives of clinical neuropsychology
Issue:
Volume 37:Number 5(2022)
Page Start:
1045
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. DOP46 Extended induction treatment with mirikizumab in patients with moderately to severely active ulcerative colitis: results from a Phase 2 trial. (25th January 2019)

Authors:
Sandborn, W J; Ferrante, M; Bhandari, B R; Berliba, E; Hibi, T; D'Haens, G Geert R; Tuttle, J; Krueger, K; Friedrich, S; Durante, M; Arora, V; Feagan, B
Journal:
Journal of Crohn's and colitis
Issue:
Volume 13(2019)Supplement 1
Page Start:
S054
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. DOP52 Reduction in inflammatory biomarkers in a Phase 2 study of mirikizumab in patients with moderately to severely active ulcerative colitis. (25th January 2019)

Authors:
Sandborn, W J; Sands, B; Kobayashi, T; Tuttle, J; Schmitz, J; Durante, M; Higgs, R; Canavan, J B; Siegel, R; Ferrante, M
Journal:
Journal of Crohn's and colitis
Issue:
Volume 13(2019)Supplement 1
Page Start:
S059
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. OP28 Gene expression (GE) values in a phase 2 trial of mirikizumab in ulcerative colitis (UC) correlate better with histopathology (HP) than endoscopy (EN) and Mayo scores. (15th January 2020)

Authors:
Steere, B; GOTTLIEB, K; Schmitz, J; Higgs, R; Jia, B; Milch, C; Tuttle, J; Krishnan, V; Belin, R; Reinisch, W
Journal:
Journal of Crohn's and colitis
Issue:
Volume 14(2020)Supplement 1
Page Start:
S025
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. OP38 Maintenance treatment with mirikizumab, a p19-directed IL-23 antibody: 52-week results in patients with moderately-to-severely active ulcerative colitis. (25th January 2019)

Authors:
D'Haens, G Geert R; Sandborn, W J; Ferrante, M; Bhandari, B R; Berliba, E; Hibi, T; Tuttle, J; Canavan, J B; Friedrich, S; Durante, M; Arora, V; Feagan, B
Journal:
Journal of Crohn's and colitis
Issue:
Volume 13(2019)Supplement 1
Page Start:
S026
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗